Genexpressionstests haben sich in der Tumorversorgung zu einer wertvollen Methodik entwickelt, um die Einschätzung des individuellen Rückfallrisikos zu optimieren. Auch für das maligne Melanom der Haut stehen nun derartige Tests zur Verfügung. Sie können Ärzten helfen, gemeinsam mit ihren Patienten die weitere Therapie dem individuellen Risiko anzupassen.
Literatur
Eggermont AMM, Robert C. New drugs in melanoma: it’s a whole new world. Eur J Cancer. 2011;47(14):2150–7.
Schadendorf D, Hauschild A. Melanoma in 2013: Melanoma—the run of success continues. Nat Rev Clin Oncol. 2014;11(2):75–6.
Zhu Z et al. The rapidly evolving therapies for advanced melanoma — Towards immunotherapy, molecular targeted therapy, and beyond. Crit Rev Oncol Hematol. 2016;99:91–9.
Meckbach D et al. Survival according to BRAF-V600 tumor mutations — an analysis of 437 patients with primary melanoma. PLoS One. 2014;9(1):e86194.
Thomas NE et al. Association Between NRAS and BRAF Mutational Status and Melanoma- Specific Survival Among Patients With Higher-Risk Primary Melanoma. JAMA Oncol. 2015;1(3):359–68.
Balch CM et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206.
Gerami P et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res. 2015;21(1):175–83.
http://skinmelanoma.com/decisiondx-melanoma-test/understanding-the-results/
Brunner G et al. Increased expression of the tumor suppressor PLZF is a continuous predictor of long-term survival in malignant melanoma patients. Cancer Biother Radiopharm. 2008;23(4):451–9.
Brunner G et al. A nine-gene signature predicting clinical outcome in cutaneous melanoma. J Cancer Res Clin Oncol. 2013;139(2):249–58.
Brunner G et al. Independent validation of a prognostic gene-signature based risk score in formalin-fixed paraffin-embedded melanomas. Cancer Res. 2014;74(19 Suppl):Abstr 2861.
Whiteman DC et al. More people die from thin melanomas (≤ 1 mm) than from thick melanomas (> 4 mm) in Queensland, Australia. J Invest Dermatol. 2015;135(4):1190–3.
AJCC Cancer Staging Manual, 8th Edition. New York Heidelberg Dordrecht London: Springer; 2017.
Morton DL et al. Final trial report of sentinel-node biopsy versus observation in melanoma. N Engl J Med. 2014;370(7):599–609.
van der Ploeg AP et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol. 2011;29(16):2206–14.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Reinhold, U., Dirschka, T. Personalisiertes Risikomanagement für das maligne Melanom. Im Focus Onkologie 21, 18–20 (2018). https://doi.org/10.1007/s15015-018-3878-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15015-018-3878-1